As of 2025-05-16, the EV/EBITDA ratio of PTC Therapeutics Inc (PTCT) is -89.05. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PTCT's latest enterprise value is 5,179.65 mil USD. PTCT's TTM EBITDA according to its financial statements is -58.17 mil USD. Dividing these 2 quantities gives us the above PTCT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 13.7x | 13.5x |
| Forward P/E multiples | 12.9x - 15.2x | 13.8x |
| Fair Price | (30.08) - (30.44) | (30.43) |
| Upside | -166.4% - -167.2% | -167.2% |
| Date | EV/EBITDA |
| 2025-05-15 | -89.05 |
| 2025-05-14 | -91.00 |
| 2025-05-13 | -90.52 |
| 2025-05-12 | -90.00 |
| 2025-05-09 | -87.59 |
| 2025-05-08 | -85.25 |
| 2025-05-07 | -82.88 |
| 2025-05-06 | -76.68 |
| 2025-05-05 | -82.73 |
| 2025-05-02 | -95.34 |
| 2025-05-01 | -94.76 |
| 2025-04-30 | -95.19 |
| 2025-04-29 | -94.76 |
| 2025-04-28 | -95.09 |
| 2025-04-25 | -94.77 |
| 2025-04-24 | -94.80 |
| 2025-04-23 | -95.34 |
| 2025-04-22 | -92.96 |
| 2025-04-21 | -92.96 |
| 2025-04-17 | -91.87 |
| 2025-04-16 | -90.54 |
| 2025-04-15 | -91.26 |
| 2025-04-14 | -88.74 |
| 2025-04-11 | -85.89 |
| 2025-04-10 | -82.24 |
| 2025-04-09 | -85.58 |
| 2025-04-08 | -81.54 |
| 2025-04-07 | -85.67 |
| 2025-04-04 | -86.24 |
| 2025-04-03 | -90.98 |
| 2025-04-02 | -93.20 |
| 2025-04-01 | -90.80 |
| 2025-03-31 | -96.71 |
| 2025-03-28 | -101.16 |
| 2025-03-27 | -102.18 |
| 2025-03-26 | -102.61 |
| 2025-03-25 | -103.91 |
| 2025-03-24 | -104.94 |
| 2025-03-21 | -105.09 |
| 2025-03-20 | -104.40 |
| 2025-03-19 | -104.88 |
| 2025-03-18 | -102.83 |
| 2025-03-17 | -105.13 |
| 2025-03-14 | -101.51 |
| 2025-03-13 | -99.15 |
| 2025-03-12 | -100.31 |
| 2025-03-11 | -98.92 |
| 2025-03-10 | -98.79 |
| 2025-03-07 | -98.92 |
| 2025-03-06 | -99.21 |